Search
Search Results
##search.searchResults.foundPlural##
-
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1393PDF: 1140HTML: 268 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1830PDF: 1383HTML: 658 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2240PDF: 904HTML: 374 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2321PDF: 1694HTML: 684 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2598HTML: 323PDF: 965 -
IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA
2670PDF: 1245HTML: 169 -
IMPACT OF QUALITATIVE AND QUANTITATIVE IMMUNOPARESIS ON EARLY INFECTION RISK IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA Immunoparesis and early infection risk in myeloma
238PDF: 745HTML: 70 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2397PDF: 1881HTML: 1009 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3427PDF: 1003HTML: 4066 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2601PDF: 850HTML: 1750 -
SOLITARY PLASMACYTOMA
4258PDF: 2270HTML: 1417fIGURES 1,2: 274 -
-
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2648PDF: 1789HTML: 698 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7934PDF: 2513HTML: 2151Table 1.: 270Table 2.: 279Table 3.: 260Table 4.: 257 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1666HTML: 693PDF: 909 -
ANTIBACTERIAL RESISTANCE IN PATIENTS WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION
4205PDF: 1321HTML: 2126Table 1: 233 -
IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy
2027PDF: 867HTML: 257 -
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS
2724PDF: 932HTML: 2140 -
-
HEMATOLOGY PATIENT PROTECTION DURING THE COVID-19 PANDEMIC IN ITALY: A NATIONWIDE NURSING SURVEY Hematology patient protection during the COVID-19
1808PDF: 660HTML: 302 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3953PDF: 1754HTML: 11926Figures Haase: 265 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3572PDF: 1358HTML: 2400Fi.1 Gritti.Rambaldi: 257 -
DISTRIBUTION OF DNA DAMAGE REPAIR GENE POLYMORPHISM hOGG1, XRCC1 and p53 AMONG SICKLE CELL DISEASE PATIENTS IN INDIA
1650PDF: 839HTML: 1541Table Genotype and allele frequencies of hOGG1 codon 326 Ser>Cys and p53 72Arg>Pro polymorphisms among SCD patients and control group: 218
1 - 43 of 43 items







